Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2015, Article ID 169069, 10 pages
Review Article

Modulation of miRNAs in Pulmonary Hypertension

Sudhiranjan Gupta1,2,3 and Li Li1,4

1Division of Molecular Cardiology, Department of Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76504, USA
2Baylor Scott & White Health, Temple, TX 76508, USA
3Central Texas Veterans Health Care System, Temple, TX 76504, USA
4Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100191, China

Received 19 December 2014; Revised 18 February 2015; Accepted 21 February 2015

Academic Editor: Nitish R. Mahapatra

Copyright © 2015 Sudhiranjan Gupta and Li Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and vascular diseases. They are a class of small, noncoding RNAs that contributes crucial roles typically through binding of the 3′-untranslated region of mRNA. A single miRNA may influence several signaling pathways associated with cardiac remodeling by targeting multiple genes. Pulmonary hypertension (PH) is a rare disorder characterized by progressive obliteration of pulmonary (micro) vasculature that results in elevated vascular resistance, leading to right ventricular hypertrophy (RVH) and RV failure. The pathology of PH involves vascular cell remodeling including pulmonary arterial endothelial cell (PAEC) dysfunction and pulmonary arterial smooth muscle cell (PASMC) proliferation. There is no cure for this disease. Thus, novel intervention pathways that govern PH induced RVH may result in new treatment modalities. Current therapies are limited to reverse the vascular remodeling. Recent studies have demonstrated the roles of various miRNAs in the pathogenesis of PH and pulmonary disorders. This review provides an overview of recent discoveries on the role of miRNAs in the pathogenesis of PH and discusses the potential for miRNAs as therapeutic targets and biomarkers of PH at clinical setting.